CANCER COMMUN 润色咨询

Cancer Communications

出版年份：2015 年文章数：220 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：8.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2023-11-01 ms6000000767028824 来自广西

    审稿速度:12.0 | 投稿命中率:50.0
    经验分享：审稿2个月以上，返修2次，总时长超过6个月

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-03-03 life2020hard

    10天了还在，initial checking.......

    14

    展开14条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2023-06-29 侠胆医心 来自香港

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：转化医学;肿瘤转移;鼻咽癌
    经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。
    在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。
    Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2023-04-23 ms6000001944827421 来自上海

    垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2021-03-23 zyn930812

    最近有人投吗？一周多了，还在初审呢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2020-12-02 152244e1c4m

    投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2021-03-26 mmz2101863

    提交一周后under review，坐等。

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-08-19 148c7eccm12(暂无昵称)

    感觉是第二个molecular cancer

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-09-13 ms9000001345306664

    请问pending decision是什么意思？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享：审稿2个月以上，返修2次，总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在，initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：转化医学;肿瘤转移;鼻咽癌<br>经验分享：2023年6月28日，科睿唯安（Clarivate Analytics）发布了2022年期刊引证报告（Journal Citation Reports，JCR）。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2，位列全球241本 Oncology 学科类期刊第15位（Q1区）。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中，Cancer Communications 再次进入医学大类1区Top期刊行列，同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展，期刊学术影响力不断提升，逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人，审稿意见粗看言辞犀利细看狗屁不通，导致编辑直接给拒了，最离谱的就是指着一个EdU实验图说我IF染色分子定位不对，而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗？我文章里连IF都没提到过，能不能不要找连实验都没做过的人来审稿？别耽误人了行不行，简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗？一周多了，还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周，还在格式审查，编号1100+，难道现在投稿数这么多吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951373, encodeId=63a69513e31e, content=提交一周后under review，坐等。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210306/c43b318bec32425a9676f05399c0cd55/11d43e45561e4c748a631fc4a900607e.jpg, createdBy=5bff5319966, createdName=mmz2101863, createdTime=Fri Mar 26 13:03:37 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239764, encodeId=83df1239e64d4, content=感觉是第二个molecular cancer, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a7845329653, createdName=148c7eccm12(暂无昵称), createdTime=Fri Aug 19 16:46:45 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248631, encodeId=b3bb1248631d2, content=请问pending decision是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f36473924, createdName=ms9000001345306664, createdTime=Tue Sep 13 11:52:14 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189359, encodeId=87e3118935938, content=请问Pending Recommendation一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f58f2333687, createdName=122766cam31(暂无昵称), createdTime=Sun Jan 30 20:10:32 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-01-30 122766cam31(暂无昵称)

    请问Pending Recommendation一般多久？

    4

    展开4条回复
共133条页码: 1/14页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分